{
    "ticker": "NBSM",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage immunotherapy company dedicated to the development and commercialization of innovative therapies that harness the immune system to fight cancer and other diseases. Founded in 2015 by Dr. Patrick Soon-Shiong, a renowned surgeon and entrepreneur, NantKwest is at the forefront of cell-based immunotherapy, focusing on natural killer (NK) cell technology. The company's proprietary platform utilizes these NK cells to develop treatments that have the potential to target tumors and enhance the body\u2019s immune response against cancer. NantKwest is currently engaged in various clinical trials aimed at evaluating the safety and efficacy of its NK cell therapies in patients with different types of cancer, including breast cancer and pancreatic cancer. The company's mission is to transform cancer care through groundbreaking immunotherapy solutions, improving patient outcomes and quality of life. NantKwest is also exploring partnerships and collaborations with other biotech firms and research institutions to expand its research capabilities and accelerate the development of its therapies. By leveraging advanced technology and a patient-centered approach, NantKwest aims to revolutionize the way cancer is treated and make a significant impact in the field of oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Culver City, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "Dr. Patrick Soon-Shiong",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://ir.nantkwest.com",
    "key_executives": [
        {
            "name": "Dr. Patrick Soon-Shiong",
            "position": "CEO"
        },
        {
            "name": "Dr. Mark M. S. Choi",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "NK Cell Therapy"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Explore NantKwest, Inc., a leader in immunotherapy focused on harnessing NK cells to combat cancer. Discover our innovative therapies and commitment to transforming cancer treatment.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "NK Cells",
            "Cancer Treatment",
            "Biotechnology",
            "Patrick Soon-Shiong"
        ]
    },
    "faq": [
        {
            "question": "What is NantKwest known for?",
            "answer": "NantKwest is known for its innovative NK cell immunotherapy aimed at treating cancer."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "Dr. Patrick Soon-Shiong is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Culver City, California, USA."
        },
        {
            "question": "What are NantKwest's main products?",
            "answer": "NantKwest's main product is its NK cell therapy, which is currently in clinical trials."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "CELG",
        "KITE",
        "BMY",
        "GILD"
    ],
    "related_stocks": [
        "JNJ",
        "AMGN",
        "REGN",
        "NVDA"
    ]
}